ALFA Finder| Value | ₹0.24 Cr |
|---|
BSE filing, NSE: GUFICBIO. Summary written from the filing by ALFA Finder's alert engine.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹436.30
- Market cap
- ₹4,375 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 59.6×Sector 48.6×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Board Meeting Date
Gufic Biosciences gives notice of a board meeting on 14 November 2026 to consider unaudited standalone and consolidated quarterly results. The filing carries no financial figures or business decision.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences' tax dispute moved after the ITAT remanded matters to the Assessing Officer. The residual Rs. 11.76 lakh demand will be redetermined in fresh assessment.
- Value
- ₹0.12 Cr
Gufic BioSciences Legal & Regulatory
Gufic Biosciences disclosed an ITAT Mumbai order for AY 2023-24 that set aside the CIT(A) findings and restored the matter to the Assessing Officer. No demand arises from the order, and the tax liability will be determined after fresh assessment.
Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr
Other merger & restructuring announcements
All →Jubilant Ingrevia Merger & Restructuring
Jubilant Ingrevia updated on a restructuring share subscription and purchase agreement closing in two tranches. First tranche is due by November 2026, second by September 2027.
- Execution
- First tranche by November 2026; second tranche by September 2027
Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
AAA Technologies Merger & Restructuring
AAA Technologies approved four wholly owned subsidiaries in Singapore, Mauritius, Dubai and India. Each entity is in IT security, cybersecurity and technology services.
Tirupati Starch & Chemicals Merger & Restructuring Worth ₹2.98 Cr
Tirupati Starch agreed to sell its Indore immovable property to Usha and Arpit Doshi for Rs 2.98 Crore. Completion is expected by 15 January 2027, subject to conditions.
- Value
- ₹2.98 Cr
- Execution
- Completion expected on or before 15 January 2027
CFF Fluid Control Merger & Restructuring
CFF Fluid Control will form a 51% joint venture with TKMS Atlas Elektronik for anti-submarine warfare in India. No deal value is disclosed.
Trom Industries Merger & Restructuring Worth ₹0.02 Cr
Trom Industries plans to incorporate Trom Energy SPV Private Limited, a solar power subsidiary, holding 98%. The initial cash subscription is Rs 1,96,000 for 19,600 shares.
- Value
- ₹0.02 Cr